4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

4 - Ainos, Inc. (0001014763) (Issuer)

SC 13D/A - Ainos, Inc. (0001014763) (Subject)

SC 13D - Ainos, Inc. (0001014763) (Subject)

SC 13D/A - Ainos, Inc. (0001014763) (Subject)

SC 13D/A - Ainos, Inc. (0001014763) (Filed by)

SC 13D/A - Ainos, Inc. (0001014763) (Filed by)

SC 13D/A - Ainos, Inc. (0001014763) (Subject)

SC 13D/A - Ainos, Inc. (0001014763) (Subject)

SC 13D/A - Ainos, Inc. (0001014763) (Subject)

Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.Key Highlights from the Report:AI Nose Technolog

SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below

Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform developmentFrom giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.Dear Share

From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.Dear Shareholders,As 2024 draws to a close, I am honored to share Ainos, Inc.'s significant achievements this year. Guided by our commitment to

SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its participation in the Webull Corporate Connect Service (CCS). This initiative aims to further expand the Company's investor outreach and enhance transparency with its growing shareholder base.By joining the Webull Corporate Connect Service, Ainos gains access to a dynamic digital platform that facilitates real-time communication with shareholders and retail investors. The Ainos page on CCS will showcase the Company's corporate m

SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research has issued a report highlighting Ainos' strategic partnership with Taiwan Tanabe Seiyaku for manufacturing and marketing VELDONA®, a novel therapeutic candidate for primary Sjögren's syndrome, in Taiwan.The report underscores the significance of Ainos' efforts to out-license VELDONA®, starting with this key regional partnership, and sets the stage for future global expansion.Key Highlights from the Report:K

Taiwan regulatory approval for the trial expected in Q1 2025Remains committed to a capital-efficient business strategySAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report on the Company's obtainment of Institutional Review Board ("IRB") approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the VELDONA® clinical study for primary Sjogren's syndrome, along with 3Q24 results and multiple other developments.Th

IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has received Institutional Review Board ("IRB") approval from Shuang Ho Hospital, affiliated with Taipei Medical University (IRB Approval No.: TMU-JIRB No.: N202408042), for its clinical trial of VELDONA® in treating Sjö

SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics, today announced it has filed complaints with NASDAQ MarketWatch and the U.S. Securities and Exchange Commission (SEC), due to concerns about unusual trading activity in its common stock, specifically large-volume sell orders. Ainos suspects that these trading activities may involve regulatory violations and urges the regulators to investigate thoroughly to uphold market fairness and protect stockholder interests.Ainos management team views this matt

Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside

Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress

Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully

Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024Advancing VELDONA drug candidates to Phase III clinical studiesExpanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and InabataSAN DIEGO, CA / ACCESSWIRE / March 8, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the year ended December 31, 2023.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ain

Product Cycle Transition Approaches its Final StagesNew Product Line Expected to Gain Momentum in the Fourth QuarterSAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the third quarter ended September 30, 2023.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "During the third quarter of 2023, we took key steps towards establishing new revenue stream

Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered TestingLaunch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the second quarter ended June 30, 2023.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "The second quarter of 2023 was a transi

Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologiesStrategic pivot is underpinned by Ainos' diversified product pipelineSAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2023.Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Th

Revenues increased by 3,832% year over yearDebt ratio improved to 7% from 75% at year-end 2021SAN DIEGO, CA / ACCESSWIRE / March 31, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the fourth quarter and full year ended December 31, 2022.Fourth Quarter 2022 Financial HighlightsRevenues were US$1,038,025 in the fourth quarter of 2022, up 3,832% year over year.Gross profit was US$459,815, up 2,668% year over year, representing a gross margin of 44.3% in the four